Risk Factors Update Summary
- Another significant communicable disease risk factor was added, expanding beyond COVID-19.
- Net cash provided by financing activities decreased significantly from $15,472,232 to $12,841,640.
- The company disclosed risks related to wars in Ukraine and the Gaza Strip.
- Proceeds from the sale of common stock and warrants decreased from $15,471,775 to $14,758,488.
- A new risk factor was added regarding potential delisting from Nasdaq due to non-compliance.
- Ending cash balance decreased from $10,723,870 to $8,320,519.
- The company initiated a share repurchase program for up to $2 million.
- The company reported a decrease in gross revenue from $88,600 in 2022 to $9,000 in 2023.
- Research and development expenses decreased from $6,268,854 in 2022 to $1,970,639 in 2023.
- The company reported a decrease in net cash used in operating activities from $7,796,966 in 2022 to $8,027,885 in 2023.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1187953&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.